• Integrative Research Centers

    Center for Clinical and Translational Research

    lee-nadler.jpgLee Nadler, MD 

    The Center for Clinical and Translational Research was established to improve the infrastructure for clinical and translational research and to develop the next generation of clinical investigators. To support the increasing number and complexity of clinical trials at Dana-Farber, the Center established the Clinical Research Center and the Clinical Research Laboratory. The Clinical Research Center provides a facility where first-in-human and proof-of-concept clinical experiments can be conducted with the highest quality and safety. The facility will double in capacity when the Yawkey Center for Cancer Care opens in 2011. The Clinical Research Laboratory was founded to ensure the accuracy and quality of specimens obtained from subjects on clinical trials. It establishes individual standard operating procedures for each clinical trial, and then processes, stores, and retrieves the human clinical research specimens, markedly improving the quality of the trial endpoints.

    Next Generation of Clinical Investigators Program

    bruce-johnson.jpgBruce Johnson, MD 
    Director: Bruce Johnson, MD

    The Next Generation of Clinical Investigators Program was established to recruit, mentor, and support a cadre of promising clinical investigators. These investigators develop collaborations with other faculty at Dana-Farber and establish partnerships with industry on first-in-human and early phase clinical trials. A grant from the Dana Foundation has funded the initial group of Next Generation Investigators; additional investigators will be recruited to the program over the next several years.


    Translational Research Laboratory

    pasi-janne.jpgPasi Jänne, MD, PhD 
    Director: Pasi Jänne, MD, PhD

    The Translational Research Laboratory (TRL), supported by a generous grant from Dunkin' Donuts, was established to define patient subsets with specific outcomes and, ultimately, to predict patient response to treatment. Technologies being offered include the isolation, enumeration, and genotyping of circulating tumor cells, determination of plasma cytokine levels, and genotypic analysis of plasma-based tumor DNA. Currently, TRL is establishing Chip-based proteomic analyses in tumor specimens.

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms